Quorum has unique proprietary expertise in the field of the human microbiome, most notably through the development of the technology platform MiNE™ (Microbiome isolates and Novel Extracts). This novel and efficient platform technology is foundational for the company’s biotherapeutics discovery efforts. MiNE™ technology allows the discovery effort to focus on high biotherapeutic yield, target-organ-relevant, safe and scalable biotherapeutics from the immediate outset.
Join our mailing list
Exclusive deals for subscribers. Stay updated with the latest news and offers.